Dr. Scott A. Reines M.D., Ph.D. Net Worth

Dr. Scott A. Reines M.D., Ph.D. biography

Dr. Scott A. Reines M.D., Ph.D. is the Interim Chief Medical Officer at Avenue Therapeutics Inc.

How old is Dr D?

Dr D is 74, he's been the Interim Chief Medical Officer of Avenue Therapeutics Inc since . There are no older and 11 younger executives at Avenue Therapeutics Inc.

What's Dr D's mailing address?

Scott's mailing address filed with the SEC is 2 Gansevoort St 9TH FLOOR, New York, NY 10014, USA.

Insiders trading at Avenue Therapeutics Inc

Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss oraz Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.

What does Avenue Therapeutics Inc do?

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

Avenue Therapeutics Inc executives and stock owners

Avenue Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lucy Lu,
  President, Chief Executive Officer, Director
• Dr. Xiaoqin Lu M.D.,
  Pres, CEO & Director
• Joseph Vazzano,
  Chief Financial Officer, Principal Financial Officer and Corporate Secretary
• Joseph Walter Vazzano,
  CFO, Principal Financial Officer & Company Sec.
• Neil Herskowitz,
  Independent Director
• Jay Kranzler,
  Independent Director
• Thomas Moore,
  Independent Director
• Dr. Lindsay Allan Rosenwald,
  Exec. Chairman
• Garrett Ingram,
  Director
• Jaideep Gogtay,
  Director
• Lindsay Rosenwald,
  Executive Chairman of the Board
• Dr. Scott A. Reines M.D., Ph.D.,
  Interim Chief Medical Officer
• Jeffrey Paley,
  Director
• Akhtar Samad,
  Director
• Scott Reines,
  Interim Chief Medical Officer
• Michael S Weiss,
  Director
• Curtis Gale Oltmans,
  Director
• Pharmaceuticals, Inc. Inva Gen,
  10% owner
• Robert L Davidow,
  10% owner
• Biotech, Inc. Fortress,
  10% owner
• David Jin,
  Interim PFO and COO
• Faith L. Charles,
  Director